- Home
- KC vs KNSA Comparison
KC vs KNSA Comparison
Compare KC & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KC | KNSA |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.4B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KC | KNSA |
|---|---|---|
| Price | $14.43 | $44.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $17.50 | ★ $52.33 |
| AVG Volume (30 Days) | ★ 1.3M | 598.3K |
| Earning Date | 03-18-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | ★ $1,268,313,014.00 | $597,973,000.00 |
| Revenue This Year | $25.79 | $62.99 |
| Revenue Next Year | $17.31 | $33.30 |
| P/E Ratio | ★ N/A | $95.77 |
| Revenue Growth | 24.11 | ★ 55.68 |
| 52 Week Low | $10.29 | $18.12 |
| 52 Week High | $22.26 | $45.50 |
Technical Indicators
Market Signals| Indicator | KC | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 58.64 |
| Support Level | $12.75 | $42.00 |
| Resistance Level | $13.47 | $45.01 |
| Average True Range (ATR) | 0.61 | 1.58 |
| MACD | 0.03 | 0.12 |
| Stochastic Oscillator | 81.02 | 80.25 |
Price Performance
Historical ComparisonAbout KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.